Alexander M. Walker

Brigham and Women's Hospital — United States

Economics, Econometrics and Finance · Social Sciences

68h-index15.8kcitations237works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(23), Pharmacovigilance and Adverse Drug Reactions(21), Statistical Methods in Clinical Trials(16), Inflammatory mediators and NSAID effects(12), Lipoproteins and Cardiovascular Health(11)

Publications237 total

Geospatial distribution of the adoption of dipeptidyl-peptidase-4 inhibitors for type 2 diabetes among Medicare beneficiaries
Spatial and Spatio-temporal Epidemiology·2025Open Access
Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database
Journal of the American Heart Association·2024· 6 citedOpen Access
Semiparametric Allocation of Subjects to Cohort Strata
Epidemiology·2023
Stratified analysis in comparative effectiveness studies that emulate randomized trials
Pharmacoepidemiology and Drug Safety·2023· 5 cited
An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose
Clinical Journal of Pain·2022· 12 citedOpen Access
Longstanding Phenytoin Use as a Cause of Progressive Dyspnea
CHEST Journal·2022· 3 cited
Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study
Journal of the Association of Medical Microbiology and Infectious Disease Canada·2021· 1 citedOpen Access
Trends of HIV Mortality between 2001 and 2018: An Observational Analysis
Tropical Medicine and Infectious Disease·2021· 14 citedOpen Access
Pregabalin Neurotoxicity Associated with Triphasic Waves on Electroencephalogram. Conservative Management or Hemodialysis?
Research in Health Science·2021Open Access
Vaccine safety: looking forward and back
BMJ Global Health·2021· 2 citedOpen Access
Complementary hypotheses in safety surveillance
Sequential Analysis·2020
Silencing Innovation: The Patent Eligibility of siRNA Therapeutics
eYLS (Yale Law School)·2020· 1 citedOpen Access
Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals
Journal of Antimicrobial Chemotherapy·2019· 7 cited
Structural and Functional Characterization of Dynamic Oligomerization in <i>Burkholderia cenocepacia</i> HMG-CoA Reductase
Biochemistry·2019· 11 cited
&lt;p&gt;Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data&lt;/p&gt;
Substance Abuse and Rehabilitation·2019· 3 citedOpen Access
Structure of HMG-CoA reductase from Burkholderia cenocepacia
2019
Conditional power for assessing population interventions
Journal of Comparative Effectiveness Research·2018· 1 citedOpen Access
Conditional power as an aid in making interim decisions in observational studies
European Journal of Epidemiology·2018· 5 cited
Removal of ineligible outcome cases reduces confounding
Clinical Epidemiology·2018· 2 citedOpen Access
Reuse of data sources to evaluate drug safety signals: When is it appropriate?
Pharmacoepidemiology and Drug Safety·2018· 21 cited
page 1 of 12Next →

Frequent Co-authors

Kenneth J. Rothman(8), Peter Boyle(6), Patrick Maisonneuve(6), Robert J. Glynn(5), Hershel Jick(5), J. Alexander Cole(5), Sebastian Schneeweiß(4), John D. Seeger(4), Witold Zatoński(4), Lee L. Lanza(3), Richard N. Watkins(3), Judith R. Hunter(3), Barbara J. Dinan(3), Sue Madsen(3), Stephen B. Soumerai(3), Peter Baghurst(3), Jeanne Loughlin(3), Tobias Kurth(2), K. Arnold Chan(2), Joan Landon(2)